Background & aims: Abnormal acid exposure time (AET) is associated with good outcomes of symptoms from antireflux therapy. Low esophageal mean nocturnal baseline impedance (MNBI) is an additional marker of reflux disease. We aimed to evaluate the value of MNBI when analysis of AET produces borderline or inconclusive results.
Methods: We studied a retrospective cohort of 371 patients (mean age, 54.5 ± 0.7 y; 60.0% female) who had persistent reflux symptoms after treatment and underwent ambulatory pH-impedance monitoring off antisecretory therapy at 1 tertiary center in Europe or 1 in the United States. Total AET was determined from pH impedance studies (pathologic, >6%; physiologic, <4%; borderline or inconclusive, 4%-6%). Baseline impedance values were calculated at the 5-cm impedance channel at 3 nocturnal 10-minute periods and averaged to yield MNBI (abnormal, <2292 ohms). The primary outcome was response to antireflux therapy, defined as global symptom improvement of 50% or greater on patients' answers on standardized visual analog scales.
Results: Among the 371 patients, 107 (28.8%) had pathologic AET and 234 (63.1%) had abnormal MNBI. Low MNBI was concordant in 99.1% of patients with pathologic AET, in 91.2% with borderline AET, and in 33.7% with physiologic AET. During 38.7 ± 0.8 months of follow-up evaluation, 43.0% of patients had improved symptoms with medical therapy and 76.2% had improved symptoms with surgical antireflux therapy (P < .0001). When MNBI was low, response to medical therapy did not differ significantly between patients with borderline AET and patients with pathologic AET (P = .44), but did differ significantly when each group was compared with patients with physiologic AET, regardless of whether MNBI was normal or low (P < .0001 for each comparison).
Conclusions: When low, MNBI identifies patients with pathologic and borderline AET who respond to antireflux therapy. MNBI analysis complements AET in defining esophageal reflux burden. MNBI correlates with response of symptoms to antireflux therapy.
Keywords: Acid Exposure Time; Baseline Impedance; GERD; pH-Impedance Monitoring.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.
Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease.Aliment Pharmacol Ther. 2016 Oct;44(8):890-8. doi: 10.1111/apt.13777. Epub 2016 Aug 24. Aliment Pharmacol Ther. 2016. PMID: 27554638 Free PMC article. Clinical Trial.
Esophageal Baseline Impedance From High-resolution Impedance Manometry Correlates With Mean Nocturnal Baseline Impedance From pHimpedance Monitoring.J Neurogastroenterol Motil. 2020 May 10. doi: 10.5056/jnm19142. Online ahead of print. J Neurogastroenterol Motil. 2020. PMID: 32388941
Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients.Neurogastroenterol Motil. 2020 Mar;32(3):e13752. doi: 10.1111/nmo.13752. Epub 2019 Oct 31. Neurogastroenterol Motil. 2020. PMID: 31670453
Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum.Ann Gastroenterol. 2018 Jan-Feb;31(1):1-7. doi: 10.20524/aog.2017.0199. Epub 2017 Oct 10. Ann Gastroenterol. 2018. PMID: 29333061 Free PMC article. Review.
Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives.Dig Dis Sci. 2017 Aug;62(8):1881-1889. doi: 10.1007/s10620-017-4625-8. Epub 2017 May 26. Dig Dis Sci. 2017. PMID: 28550489 Review.
Cited by 1 article
Measurement of Esophageal Nocturnal Baseline Impedance: A Simplified Method.J Neurogastroenterol Motil. 2020 Apr 30;26(2):241-247. doi: 10.5056/jnm19183. J Neurogastroenterol Motil. 2020. PMID: 32235031 Free PMC article.